CTi Biopharma Corp. Daily Stock Analysis

Daily Stock Analysis, CTIC, CTi Biopharma Corp, priceseries

CTi Biopharma Corp. Daily Stock Analysis
Stock Information
Open
3.82
Close
4.29
High
4.55
Low
3.79
Previous Close
3.94
Daily Price Gain
0.35
YTD High
4.55
YTD High Date
Mar 7, 2022
YTD Low
1.82
YTD Low Date
Feb 28, 2022
YTD Price Change
1.80
YTD Gain
72.29%
52 Week High
4.55
52 Week High Date
Mar 7, 2022
52 Week Low
1.43
52 Week Low Date
Dec 2, 2021
52 Week Price Change
1.22
52 Week Gain
39.74%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 20. 2017
2.60
Jan 23. 2018
3.24
21 Trading Days
24.66%
Link
LONG
Feb 9. 2018
3.21
Mar 8. 2018
3.84
18 Trading Days
19.52%
Link
LONG
May 16. 2018
4.14
May 29. 2018
4.62
8 Trading Days
11.69%
Link
LONG
Mar 1. 2019
1.10
Mar 6. 2019
1.17
3 Trading Days
6.36%
Link
LONG
Dec 10. 2019
0.99
Dec 18. 2019
1.20
6 Trading Days
21.30%
Link
LONG
Dec 19. 2019
1.30
Jan 3. 2020
1.45
9 Trading Days
11.36%
Link
LONG
Jul 15. 2020
1.38
Jul 27. 2020
1.58
8 Trading Days
14.70%
Link
LONG
Oct 1. 2020
2.48
Oct 28. 2020
3.12
19 Trading Days
25.97%
Link
LONG
Nov 10. 2020
3.31
Nov 30. 2020
3.52
13 Trading Days
6.48%
Link
LONG
Aug 4. 2021
2.50
Aug 16. 2021
2.68
8 Trading Days
7.14%
Link
LONG
Aug 27. 2021
2.85
Sep 14. 2021
3.06
11 Trading Days
7.40%
Link
LONG
Dec 13. 2021
2.00
Jan 5. 2022
2.33
16 Trading Days
16.50%
Link
Company Information
Stock Symbol
CTIC
Exchange
NasdaqCM
Company URL
http://http://www.ctibiopharma.com
Company Phone
2062827100
CEO
James A. Bianco
Headquarters
Washington
Business Address
3101 WESTERN AVENUE, SUITE 600, SEATTLE, WA 98121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000891293
About

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.

Description

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading